Answers are grounded in this paper and cite their sources.
Exit surveys and patient interviews support the primary findings from RECONNECT and provide quantitative and qualitative assessments of the impact of HSDD on patients' quality of life and the patients' perspectives on the impact of bremelanotide. Clinical trial numbers NCT02333071, NCT02338960.
No takes yet. Share an insight, caveat, or question.
Koochaki et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: